28 related articles for article (PubMed ID: 4070286)
1. The fuel to run the orphan drug engine: a medical school-based Orphan Disease Center Program.
Brewer GJ
Prog Clin Biol Res; 1985; 197():123-38. PubMed ID: 4070287
[No Abstract] [Full Text] [Related]
2. Orphan Drug Act on congressional agenda.
von Oehsen WH
Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123
[TBL] [Abstract][Full Text] [Related]
3. Orphan Drugs Information Center.
FDA Drug Bull; 1985 Apr; 15(1):9-10. PubMed ID: 3996806
[No Abstract] [Full Text] [Related]
4. Orphan Drug Act.
Van Woert MH
Prog Clin Biol Res; 1985; 197():7-9. PubMed ID: 4070300
[No Abstract] [Full Text] [Related]
5. Orphan products development and some methods for maximizing the usefulness of research on rare diseases.
Finkel MJ
Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285
[No Abstract] [Full Text] [Related]
6. Academic center approaches to orphan drug research and development.
Hauck FP; Chung EY; Van Woert MH
Prog Clin Biol Res; 1985; 197():115-22. PubMed ID: 4070286
[No Abstract] [Full Text] [Related]
7. Translation of rare disease research into orphan drug development: disease matters.
Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
[TBL] [Abstract][Full Text] [Related]
8. The role of academic institutions in the development of drugs for rare and neglected diseases.
Coles LD; Cloyd JC
Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
[TBL] [Abstract][Full Text] [Related]
9. Orphan drugs: the question of products liability.
Scharf SF
Am J Law Med; 1985; 10(4):491-513. PubMed ID: 3911776
[TBL] [Abstract][Full Text] [Related]
10. Orphan drugs. Improved medical treatment of rare diseases.
Cramer R
Ala J Med Sci; 1988 Jul; 25(3):257-67. PubMed ID: 3052135
[No Abstract] [Full Text] [Related]
11. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
Arno PS; Bonuck K; Davis M
Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
[TBL] [Abstract][Full Text] [Related]
12. Orphan drug development across Europe: bottlenecks and opportunities.
Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
Drug Discov Today; 2008 Aug; 13(15-16):670-6. PubMed ID: 18583178
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
